5:15 PM
 | 
Jan 20, 2012
 |  BC Extra  |  Company News

Allos off as CHMP recommends against approval of Folotyn

Allos Therapeutics Inc. (NASDAQ:ALTH) was off $0.15 to $1.51 on Friday after EMA's CHMP recommended against conditional approval of Folotyn pralatrexate to treat relapsed or refractory peripheral T cell lymphoma. The MAA was based on...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >